Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $185M (cash outflow) rose 22.5% year over year, ahead of the +10.8% change in trailing-twelve-month net income. Sequentially, it rose 43.9% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Net income amounted to 85.4% of revenue in FY2025, down 16.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 14 analysts of -$132.42M (-77.0%) for the fiscal year ending Dec 2026, a slowdown from the +1.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$185M+43.9% QoQ
- Last fiscal yearDec 2025
- -$575M+1.0% YoY
- LTMMar 2026
- -$608.92M+10.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.5% | +10.3% | -12.2 pp |
| 1 year | +1.0% | -77.0% | -78.0 pp |
| 3-year CAGR | -6.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (575M) USD
- Year-over-year change
- -1.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (575M) | -1.0% |
| FY2024 | 2024-12-31 | (569.18M) | +6.2% |
| FY2023 | 2023-12-31 | (606.64M) | +14.2% |
| FY2022 | 2022-12-31 | (707.42M) | -55.8% |
| FY2021 | 2021-12-31 | (454.03M) | — |
Net Income vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 net income of $608.92M is the 3rd largest of the 11 companies compared; the peer median is $184.88M.
- Its year-over-year change of +10.8% is the 5th highest of 11, against a peer median of -6.4%.
- Net income amounts to 91.0% of revenue for RARE, versus a peer median of 330.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $27.6B | +3808.4% | +35.1% | 2.7% | |
| LTM Jun 2026 | $695.45M | -11.4% | +14.4% | 97.5% | |
| LTM Mar 2026 | $608.92M | +10.8% | -6.7% | 91.0% | |
| LTM Mar 2026 | $328.6M | +96.4% | -4.1% | 412.0% | |
| LTM Mar 2026 | $290.01M | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $209.38M | -18.9% | +0.2% | — | |
| LTM Mar 2026 | $208.87M | -4.0% | +16.2% | 1154.4% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $66.14M | +249.7% | — | 454.9% | |
| LTM Jun 2026 | $38.38M | -106.1% | — | 3.8% | |
| LTM Mar 2026 | $35.71M | -24.3% | -0.3% | 7142.0% | |
| Peer median (excluding RARE) | $184.88M | -6.4% | +4.7% | 330.2% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| Deferred Income Tax | 48.67M | 0 | (1.62M) | 0 | 0 |
| Stock-Based Compensation | 104.95M | 130.38M | 135.21M | 158.03M | 153M |
| Change in Working Capital | (63.24M) | 60.24M | (15.1M) | 13.92M | (23M) |
| Accounts Receivables | (5.43M) | (12.07M) | (22.78M) | (33.6M) | (31M) |
| Inventory | (3.12M) | (9.7M) | (6.93M) | (11.21M) | (6M) |
| Accounts Payables | 2.81M | 79.85M | 2.38M | 46.99M | 24M |
| Other Working Capital | (57.49M) | 2.16M | 12.23M | 11.73M | (10M) |
| Other Non-Cash Items | 11.71M | 118.12M | (12.67M) | (52.5M) | (56M) |
| Operating Cash Flow | (338.7M) | (380.47M) | (474.81M) | (414.19M) | (466M) |
| Capital Expenditures | (73.09M) | (146.12M) | (46.77M) | (7.49M) | (6M) |
| Acquisitions (Net) | 0 | (75.03M) | 0 | 0 | 0 |
| Purchases of Investments | (1.01B) | (614.74M) | (526.38M) | (408.61M) | (186M) |
| Sales of Investments | 890.85M | 545.08M | 746.2M | 413.27M | 444M |
| Other Investing Activities | (942K) | (30.84M) | (7.55M) | (14.94M) | (16M) |
| Investing Cash Flow | (195.37M) | (291.65M) | 168M | (17.77M) | 236M |
| Debt Repayment | 0 | 0 | 0 | 0 | 392M |
| Common Stock Issued | 78.94M | 0 | 379.76M | 380.98M | 86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 39.61M | 501.21M | 8.39M | 18.26M | 0 |
| Financing Cash Flow | 118.55M | 501.21M | 388.14M | 399.24M | 478M |
| Effect of Forex Changes | (1.19M) | (1.08M) | 462K | (2.53M) | 5.47M |
| Net Change in Cash | (416.71M) | (171.98M) | 81.8M | (35.24M) | 253.47M |
| Free Cash Flow | (411.79M) | (526.59M) | (521.57M) | (421.68M) | (472M) |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.